Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cause of cancer death
in the United States, with a median survival time of only 3− 6 months for forty percent of …

Pancreatic ductal adenocarcinomas respond poorly to chemotherapy, in part due to the
dense tumor stroma that hinders drug delivery. Ultrasound (US) in combination with …

Background Many aspects of the mechanisms involved in ultrasound-mediated therapy
remain obscure. In particular, the relative roles of drug and ultrasound, the effect of the time …

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers with
survival averaging only 3 months if untreated following diagnosis. A major limitation in …

Pancreatic cancer is the third most common cancer diagnosed in the United States, with
more than 53,000 new cases in 2017. It is the fourth leading cause of cancer-related death …

Pancreatic cancer remains one of the most lethal forms of cancer with a 10-year survival of<
1%. With little improvement in survival rates observed in the past 40 years, there is a …

Background Drug delivery in polymeric micelles combined with tumor irradiation by
ultrasound results in effective drug targeting, but this technique requires prior tumor imaging …

Pancreatic ductal adenocarcinoma (PDAC) exhibits difficult penetration of most drugs,
leading to a very poor therapeutic outcome with a quite low five-year survival rate. The …

Pulsed high intensity focused ultrasound (pHIFU) is a non-invasive method that allows to
permeabilize pancreatic tumors through inertial cavitation and thereby increase the …

The paper reports the results of nanotherapy of ovarian, breast, and pancreatic cancerous
tumors by paclitaxel-loaded nanoemulsions that convert into microbubbles locally in tumor …